Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rasimcan Meral

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Current Diabetes Reports|November 9, 2018
Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and ComorbiditiesBaris Akinci, Rasimcan Meral, Elif Arioglu Oral
Current Diabetes Reports|October 30, 2018
Update on Therapeutic Options in LipodystrophyBaris Akinci, Rasimcan Meral, Elif Arioglu Oral
BMC Cancer|October 14, 2024
RAI therapy in low-risk papillary thyroid cancer: recurrence reduction and long-term outcomes in the Turkish populationSeckin Bilgic, Rasimcan Meral, M Sait Sağer, et al.
Anatolian Journal of Cardiology|July 7, 2020
Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19Naci Şenkal, Rasimcan Meral, Alpay Medetalibeyoğlu, et al.
The Journal of Clinical Endocrinology and Metabolism|October 22, 2021
Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial LipodystrophyRasimcan Meral, Noemi Malandrino, Mary Walter, et al.
Clinical Diabetes and Endocrinology|March 30, 2019
Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to MetreleptinNazanene H Esfandiari, Melvyn Rubenfire, Adam H Neidert, et al.
Obesity Facts|November 12, 2023
A Very-Low-Calorie Diet Can Cause Remission of Diabetes Mellitus and Hypertriglyceridemia in Familial Partial LipodystrophyMaria C Foss-Freitas, Özge Besci, Rasimcan Meral, et al.
Journal of the Endocrine Society|June 16, 2025
Changes After Leptin Administration in Partial Lipodystrophy and Factors Associated With Hepatic and Metabolic ResponseBaris Akinci, Nevin Ajluni, Rasimcan Meral, et al.
Endocrinology, Diabetes & Metabolism Case Reports|March 28, 2020
The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotideBaris Akinci, Rasimcan Meral, Diana Rus, et al.
International Urology and Nephrology|October 28, 2022
COSMC expression as a predictor of remission in IgA nephropathySebahat Usta Akgul, Cigdem Kekik Cinar, Yasar Caliskan, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Current Diabetes Reports|November 9, 2018
Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and ComorbiditiesBaris Akinci, Rasimcan Meral, Elif Arioglu Oral
Current Diabetes Reports|October 30, 2018
Update on Therapeutic Options in LipodystrophyBaris Akinci, Rasimcan Meral, Elif Arioglu Oral
BMC Cancer|October 14, 2024
RAI therapy in low-risk papillary thyroid cancer: recurrence reduction and long-term outcomes in the Turkish populationSeckin Bilgic, Rasimcan Meral, M Sait Sağer, et al.
Anatolian Journal of Cardiology|July 7, 2020
Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19Naci Şenkal, Rasimcan Meral, Alpay Medetalibeyoğlu, et al.
The Journal of Clinical Endocrinology and Metabolism|October 22, 2021
Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial LipodystrophyRasimcan Meral, Noemi Malandrino, Mary Walter, et al.
Clinical Diabetes and Endocrinology|March 30, 2019
Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to MetreleptinNazanene H Esfandiari, Melvyn Rubenfire, Adam H Neidert, et al.
Obesity Facts|November 12, 2023
A Very-Low-Calorie Diet Can Cause Remission of Diabetes Mellitus and Hypertriglyceridemia in Familial Partial LipodystrophyMaria C Foss-Freitas, Özge Besci, Rasimcan Meral, et al.
Journal of the Endocrine Society|June 16, 2025
Changes After Leptin Administration in Partial Lipodystrophy and Factors Associated With Hepatic and Metabolic ResponseBaris Akinci, Nevin Ajluni, Rasimcan Meral, et al.
Endocrinology, Diabetes & Metabolism Case Reports|March 28, 2020
The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotideBaris Akinci, Rasimcan Meral, Diana Rus, et al.
International Urology and Nephrology|October 28, 2022
COSMC expression as a predictor of remission in IgA nephropathySebahat Usta Akgul, Cigdem Kekik Cinar, Yasar Caliskan, et al.
Pageof 3